Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Outlines

https://doi.org/10.22037/ijpr.2017.2065

Esters of Quinoxaline 1ˏ4-Di-N-oxide with Cytotoxic Activity on Tumor Cell Lines Based on NCI-60 Panel

Author(s):
Gildardo RiveraGildardo Riveraa, Syed Shoaib Ahmad ShahSyed Shoaib Ahmad Shahb, Daniel Arrieta-BaezDaniel Arrieta-Baezc, Isidro PalosIsidro Palosd, Antonio MongueAntonio Monguee, Luvia Enid Sánchez-TorresLuvia Enid Sánchez-Torresf,*
aCentro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
bDepartment of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan.
cCentro de Nanociencias y Micro y Nanotecnología, Instituto Politécnico Nacional, Ciudad de México, México.
dDepartamento de Química Aplicada, Universidad Autónoma de Tamaulipas, Reynosa, México.
eNeglected Diseases Section, Drug R& D Unit, Center for Applied Pharmacobiology Research, University of Navarra, Pamplona, España.
fDepartamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México.
IJ Pharmaceutical Research:Vol. 16, issue 3; 953-965
Published online:Jul 31, 2017
Article type:Original Article
Received:Aug 31, 2015
Accepted:Jul 31, 2016
How to Cite:Rivera G, Ahmad Shah SS, Arrieta-Baez D, Palos I, Mongue A, et al. Esters of Quinoxaline 1ˏ4-Di-N-oxide with Cytotoxic Activity on Tumor Cell Lines Based on NCI-60 Panel. Iran J Pharm Res. 2017;16(3):e124983. doi: https://doi.org/10.22037/ijpr.2017.2065

Abstract

Keywords
Antitumor
Cancer
Drugs
Esters
Quinoxaline 1
4-di-N-oxide

Introduction

Cancer remains a major cause of death affecting millions of people and is caused by the growth and spreading of abnormal cells in an uncontrolled manner. According to the World Health Organization (WHO) cancer is a leading cause of death worldwide that accounted for 8.2 million deaths in 2012. In addition to the extensive use of irradiation and surgical treatment, chemotherapy still plays an important role for the treatment of cancer (1). In this context, the search for novel chemotherapeutic agents is an interesting and continually evolving field of cancer research. Although major advances have been made in the chemotherapeutic management of patients with certain types of cancer, the continued commitment to the laborious task of discovering new anticancer agents remains critically important.
In the course of identifying various chemical substances which may serve as leads for designing novel antitumor agents, many classes of organic compounds have been tested, with special attention being paid to nitrogen heterocycles, five- and six-membered rings. Quinoxaline (benzopyrazine) is a heterocyclic compound containing fused benzene and pyrazine rings and it is an isomer of quinazoline. Quinoxalines display diverse and interesting pharmacological activities as antibacterial, antiviral, antiparasitic and anticancer agents (2-8). Particularly, their 1ˏ4-di-N-oxide have proved to be cytotoxic agents that are active under hypoxic conditions as that of solid tumours (6, 9-12). Additionally, this kind of derivatives has shown anti-inflammatory and anti-oxidant activities both interesting properties against cancer cells (3, 13). The identification of drugs with selective toxicity toward hypoxic cells is an important objective in anticancer chemotherapy and quinoxaline 1ˏ4-di-N-oxides could provide useful hypoxia-selective therapeutic agents.
In the present work, we are interested in quinoxaline 1, 4-di-N-oxide derivatives which have been identified as a new class of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumours (11-12). It is reported that the antitumor activity can be increased by introducing electron-withdrawing groups in one of both positions 6 and 7 on the quinoxaline ring and in the unsubstituted analogues (14). Therefore, a new series of quinoxaline 1ˏ4-di-N-oxide substitutes at 7-position with esters group were synthetized and evaluated for antitumor activities using the NCI-60 human tumor cell lines screen (15).

Experimental

Chemical compounds
The Beirut reaction was the general procedure used for synthesis of quinoxaline 1ˏ4-di-N-oxide derivatives, as described in previous report (16, 17). Quinoxaline 1ˏ4-di-N-oxide derivatives (M1-M3, E1-E8 and P1-P3) synthesis was achieved by the reaction of the corresponding diketone derivative (10.6 mmol) with the appropriate benzofuroxane N-oxide (2.4 mmol) in dry chloroform (35 mL). Triethylamine (TEA) was added (1 mL) and the reaction mixture was stirred at room temperature for 3–7 days. After evaporation to dryness at low pressure, crude solid or brown oil was obtained. This was then precipitated and washed by adding diethyl ether, affording the target compound. The residue was purified by column chromatography on silica gel, when necessary using dichloromethane: methanol (95:5). Quinoxaline di-reduced (DR1-DR3) was achieved by the reaction of the corresponding quinoxaline 1ˏ4-di-N-oxide with sodium dithionite (18). All compounds were characterized by infrared (IR), proton nuclear magnetic resonance (1H-NMR) spectroscopy, and elemental analysis.
Methyl quinoxaline-7-carboxylate 1ˏ4-di-N-oxide derivatives
Methyl2-amide-3-methylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (M1)
This compound was obtained in 10% yield from methyl benzofuroxane-5-carboxylate N-oxide and acetoacetamide. IR (KBr): 3310 (NH), 2992 (ArC-H), 1702 (C=O), 1331 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.48 (s, 3H, CH3), 3.98 (s, 3H, CH3OOC), 8.25 (s, 2H, NH2), 8.37-8.42 (m, 1H, H5), 8.57-8.62 (m, 1H, H6), 8.94 (s, 1H, H8). Calculated analysis for C12H11N3O5: C, 51.98; H, 3.97; N, 15.16. Found: C, 51.72; H, 3.63; N, 14.86.
Dimethyl3-methylquinoxaline-2, 7-dicarboxylate 1, 4-di-N-oxide (M2)
This compound was obtained in 12% yield from methyl benzofuroxane-5-carboxylate N-oxide and methyl acetoacetate. IR (KBr): 1715.30 (C=O), 1333.57 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.44 (s, 3H, CH3), 3.97 (s, 3H, COOCH3), 4.03 (s, 3H, CH3OOC), 8.38 (d, J= 8.93 Hz, 1H, H5), 8.56 (d, J= 8.89 Hz, 1H, H6), 8.85(s, 1H, H8). Calculated analysis for C13H12N2O6: C, 53.43; H, 4.14; N, 9.59. Found: C, 53.29; H, 3.97; N, 9.45.
Methyl 2-acetyl-3 trifluoromethylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (M3)
This compound was obtained in 17.7% yield from methyl benzofuroxane-5-carboxylate N-oxide and 1,1, 1-trifluoro-2,4-pentanedione. IR (KBr): 2962 (Ar C-H), 1732 (C=O), 1337 (N - oxide), 1236 and 1173 (Ar-CF3) cm-1. 1H NMR (400 MHz, DMSO-d6) ppm: 2.62 (s, 3H, COCH3), 3.99 (s, 3H, CH3OOC), 8.51 (d, J= 8.95, Hz, 1H, H5), 8.58 (d, J= 8.94, 1H, H6), 8.92 (s, 1H, H8). Calculated analysis for C13H9F3N2O5: C, 47.28; H, 2.75; N, 8.48. Found: C, 47.01; H, 2.56; N 8.45.
Ethyl quinoxaline-7-carboxylate 1ˏ4-di-N-oxide derivatives
Ethyl2-acetyl-3-methyl-quinoxaline-7-carboxylate 1ˏ4-di-N-oxide (E1)
This compound was obtained in 28% yield from ethylbenzofuroxane-5-carboxylate N-oxide and 2, 4-pentanedione. IR (KBr): 2965 (ArC-H), 1722 (C=O), 1335 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.40 (t, J= 7.10 Hz, 3H, CH3CH2OOC), 2.38 (s, 3H, CH3), 2.66 (s, 3H, COCH3), 4.4 (q, J= 7.09 Hz, 2H, CH3CH2OOC), 8.37 (d, J= 8.93 Hz, 1H, H5), 8.5 (d, J= 8.94 Hz, 1H, H6), 8.92 (s, 1H, H8). Calculated analysis for C14H14N2O5: C, 57.93; H, 4.82; N, 9.65. Found: C, 57.68; H, 4.51; N, 9.18.
Ethyl2-benzoyl-3-methylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (E2)
This compound was obtained in 12.3% yield from ethyl benzofuroxane-5-carboxylate N-oxide and 1-phenyl-1, 3-butanedione. IR (KBr): 2979 (ArC-H), 1720 and 1684 (C=O), 1331 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.41 (t, J= 7.11 Hz, 3H, CH3CH2OOC), 2.32 (s, 3H, CH3), 4.46 (q, J1= 7.10 Hz, J2= 7.13 Hz, 2H, CH3CH2OOC), 7.6 (t, J= 7.8 Hz, 2H, H3 and H5, C6H5), 7.79 (t, J= 7.43 Hz, 1H, H4, C6H5), 8.1 (d, J= 7.34 Hz, 2H, H2 and H6, C6H5), 8.38 (d, J= 8.9 Hz, 1H, H5), 8.5 (d, J= 8.94 Hz, 1H, H6), 8.99 (s, 1H, H8). Calculated analysis for C19H16N2O5: C, 64.77; H, 4.58; N, 7.95. Found: C, 64.58; H, 4.32; N, 7.67.
Ethyl 2-phenylamide-3-methylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (E3)
This compound was obtained in 22.4% yield from ethyl benzofuroxane-5-carboxylate N-oxide and 3-oxo-N-phenylbutanamide. IR (KBr): 2981 (ArC-H), 1714 and 1661 (C=O), 1369 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.36 (m, 3H, CH3CH2OOC), 2.51 (s, 1H, CH3), 4.39-4.47 (q, J1= 7.10 Hz, J2= 7.22 Hz, 2H, CH3CH2O), 7.20 (t, J= 7.34 Hz, 1H, H4-NHC6H5), 7.41 (t, J= 7.16 Hz, 2H, H3 and H5, NHC6H5), 7.65 (d, J= 7.84 Hz, H2 and H6, NHC6H5), 8.39 (d, J= 8.98 Hz, 1H, H5), 8.59 (d, J= 8.97 Hz, 1H, H6), 8.96 (s, 1H, H8), 11.10 (s, 1H, NH). Calculated analysis for C19H17N3O5: C, 62.12; H, 4.66; N, 11.44. Found: C. 61.98; H, 4.49; N, 11.23.
Ethylmethyl-3-methyl-quinoxaline-2 ,7-dicarboxilate 1ˏ4-di-N-óxide (E4)
This compound was obtained in 10% yieldfromethylbenzofuroxane-5-carboxylate N-oxide and methyl acetoacetate. IR (KBr): 1715.30 and 1726.88 (C=O), 1327.65 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.35 (s, 3H, CH3CH2OOC), 2.44 (s, 3H, CH3), 4.03 (s, 3H, COOCH3), 4.48 (q, J1= 7.08 Hz, J2= 7.07 Hz, 2H, CH3CH2OOC), 8.39 (d, J= 8.99 Hz, 1H, H5), 8.56 (d, J= 8.99 Hz, 1H, H6), 8.84 (s, 1H, H8). Calculated analysis for C14H14N2O6: C, 54.90; H, 4.61; N, 9.15. Found: C, 54.76; H, 4.27; N, 9.13
Ethyl 2-acetyl-3-trifluoromethylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (E5)
This compound was obtained in 11.9% yield from ethyl benzofuroxane-5-carboxylate N-oxide and 1,1, 1-trifluoro-2,4-pentanedione. IR (KBr): 2978 (ArC-H), 1746 (C=O), 1355 (N-oxide), 1271 and 1158 (Ar-CF3) cm-1. 1H NMR (400 MHz, DMSO-d6) ppm: 1.40 (t, J= 7.11 Hz, 3H, CH3CH2OOC), 2.62 (s, 3H, COCH3), 4.45 (q, J1= 7.12 Hz, J2= 7.13 Hz, 2H, CH3CH2OOC), 8.52 (d, J= 8.95 Hz, 1H, H5), 8.58 (d, J= 8.96 Hz, 1H, H6), 8.92 (s, 1H, H8). Calculated analysis for C14H11 F3N2O5: C, 48.85; H, 3.22; N, 8.14. Found: C, 48.58; H, 3.15; N, 8.23.
Ethyl2-(thiophene-2-carbonyl)-3-trifluoromethylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (E6)
This compound was obtained in 23.2% yield from ethyl benzofuroxane-5-carboxylate N-oxide and 4,4,4-trifluoro-1-(2-thienyl)-1,3-butanedione. IR (KBr): 2987 (ArC-H), 1726 and 1665 (C=O), 1336 (N-oxide), 1286 and 1161 (Ar-CF3) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.41 (t, J= 7.1 Hz, 3H, CH3CH2OOC), 4.47 (q, J1= 7.07 Hz, J2= 7.12 Hz, 2H, CH3CH2OOC), 7.32 (d, J= 4.7 Hz, 1H, H4, C4H3S), 8.24 (d, J= 4.59 Hz, H5, C4H3S), 8.3 (d, J= 4.8 Hz, H3, C4H3S), 8.51 (d, J= 8.95 Hz, 1H, H5), 8.56 (d, J= 8.96 Hz, 1H, H6), 8.96 (s, 1H, H8). Calculated analysis for C17H11F3N2O5S: C, 49.52; H, 2.69; N, 6.79. Found: C, 49.36; H, 2.45; N, 6.43.
Ethyl2-(naphthyl-2-carbonyl)-3-trifluoromethylquinoxaline-7-carboxylate1ˏ4-di-N-oxide (E7)
This compound was obtained in 11.3% yield from ethyl benzofuroxane-5-carboxylate N-oxide and 4, 4, 4-trifluoromethyl-1-(2-naphthyl)-1, 3-butanedione. IR (KBr): 2979 (ArC-H), 1725 and 1687 (C=O), 1349 (N-óxido), 1285 and 1174 (Ar-CF3) cm-1. 1H NMR (400 MHz, DMSO-d6) ppm: 1.42 (t, J= 7.10 Hz, 3H, CH3CH2OOC), 4.48 (q, J1= 7.08 Hz, J2= 7.11 Hz, 2H, CH3CH2OOC), 7.65 (t, J= 7.5 Hz, 1H, H3, C10H7), 7.75 (t, J= 7.2 Hz, 1H, H6, C10H7), 8.01 (d, J= 8.12 Hz, 1H, H7, C10H7), 8.07 (d, J= 8.14 Hz, 1H, H5, C10H7), 8.14 (s, 2H, H2, and H4 C10H7), 8.52-8.58 (m, 2H, H5 and H6), 8.88 (s, 1H, H8), 9.02 (s, 1H, H8, C10H7). Calculated analysis for C23H15F3N2O5: C, 60.53; H, 3.31; N, 6.14. Found: C, 60.23; H, 3.15; N, 5.89.
Ethyl 2-phenylamide-3-phenylquinoxaline-7-carboxylate 1, 4-di-N-oxide (E8)
This compound was obtained in 31.0% yield from ethyl benzofuroxane-5-carboxylate N-oxide and 3-oxo-N , 3-diphenylpropanamide. IR (KBr): 3110 (N-H), 2950 (ArC-H), 1718 and 1694 (C=O), 1334 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.41 (t, J= 7.11Hz, 3H, CH3CH2OOC), 4.45 (q, H= 7.12 Hz, 2H, CH3CH2OOC), 7.11 (t, J= 7.25 Hz, 1H, H4, NHC6H5), 7.31 (t, J= 7.88 Hz, 2H, H3 and H5, C6H5), 7.38 (d, J = 8.23 Hz, 2H, H3 and H5, NHC6H5), 7.48-7.50 (m, 3H, C6H5), 7.61-7.63 (m, 2H, H2 and H6, NHC6H5), 8.49 (d, J= 8.96 Hz, H5), 8.69 (d, J= 8.94 Hz, 1H, H6), 9.02 (s, 1H, H8), 10.86 (s, 1H, NH). Calculated analysis for C24H19N3O5: C, 67.13; H, 4.42; N, 9.79. Found: C, 66.95; H, 4.21; N, 9.52.
n-propil quinoxaline-7-carboxylate 1ˏ4-di-N-oxide derivatives
n-propyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (P1)
This compound was obtained in 8.3% yield from n-propyl benzofuroxane-5-carboxylate N-oxide and 1-phenyl-1, 3-butanedione. IR (KBr): 2978 (ArC-H), 1718 and 1685 (C=O), 1332 (N-oxide) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.02 (t, J= 7.38 Hz, 3H, CH3CH2CH2OOC), 1.81 (q, J1= 6.76 and J2= 14.12 Hz, 2H, CH3CH2CH2OOC), 4.39 (t, J= 6.62 Hz, 2H, CH3CH2CH2OOC), 7.61 (t, J= 7.82 Hz, 2H, H3 and H5, C6H5), 7.80 (t, J= 7.40 Hz, 1H, H4, C6H5), 8.12 (d, J= 7.30 Hz, 2H, H2 and H6, C6H5), 8.39 (d, J= 8.9 Hz, 1H, H5), 8.51 (d, J= 8.90 Hz, 1H, H6), 8.98 (s, 1H, H8). Calculated analysis for C20H18N2O5: C, 65.57; H, 4.91; N, 7.65. Found: C, 65.38; H, 4.63; N, 7.37.
n-propyl2-phenylamide-3methylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (P2)
This compound was obtained in 10.4% yield from n-propyl benzofuroxane-5-carboxylate N-oxide and 3-oxo-N-phenylbutanamide. IR (KBr): 2982 (ArC-H), 1716 and 1672 (C=O), 1332 (N-oxide), cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.03 (t, J= 7.40 Hz, 3H, CH3CH2CH2OOC), 1.82 (q, J1= 6.77 and J2= 14.11 Hz, 2H, CH3CH2CH2OOC), 4.38 (t, J= 6.60 Hz, 2H, CH3CH2CH2OOC), 7.21 (t, J= 7.32 Hz, 1H, H4-NHC6H5), 7.42 (t, J= 7.20 Hz, 2H, H3 and H5, NHC6H5), 7.64 (d, J= 7.80 Hz, H2 and H6, NHC6H5), 8.38 (d, J= 8.90 Hz, 1H, H5), 8.58 (d, J= 8.90 Hz, 1H, H6), 8.95 (s, 1H, H8), 11.12 (s, 1H, NH). Calculated analysis for C20H19N3O5: C, 62.99; H, 4.98; N, 11.02. Found: C. 62.58; H, 4.61; N, 10.87.
n-propyl2-benzoyl-3-trifluoromethylquinoxaline-7-carboxylate 1ˏ4-di-N-oxide (P3)
This compound was obtained in 5.9% yield from n-propyl benzofuroxane-5-carboxylate N-oxide and 4, 4,4-trifluoro-1-phenyl-1,3-butanedione. IR (KBr): 2982 (Ar C-H), 1728 and 1688 (C=O), 1336 (N-oxide), 1254 and 1166 (Ar-CF3) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 1.02 (t, J= 7.40 Hz, 3H, CH3CH2CH2OOC), 1.82 (q, J1= 6.77 and J2= 14.11 Hz, 2H, CH3CH2CH2OOC), 4.39 (t, J= 6.58 Hz, 2H, CH3CH2CH2OOC), 7.62 (t, J= 7.84 Hz, 2H, H3 and H5, C6H5), 7.79 (t, J= 7.43 Hz, 1H, H4, C6H5), 8.15 (d, J= 7.26 Hz, 2H, H2 and H6, C6H5), 8.52-8.54 (m, 2H, H5 and H6), 8.98 (s, 1H, H8). Calculated analysis for C20H15F3N2O5: C, 57.14; H, 3.57; N, 6.66. Found: C, 56.91; H, 3.39; N, 6.37.
Quinoxaline-7-carboxylate derivatives
Methyl2-amide-3-methylquinoxaline-7-carboxylate (DR1)
This compound was obtained in 4% yield from methyl 2 -amide-3-methylquinoxaline-7-carboxylate 1, 4-di-N-oxide by di-reduced using sodium dithionite. IR (KBr): 3312 (NH), 2994 (ArC-H), 1702 (C=O) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.48 (s, 3H, CH3), 3.98 (s, 3H, CH3OOC), 8.25 (s, 2H, NH2), 8.37-8.42 (m, 1H, H5), 8.57-8.62 (m, 1H, H6), 8.94 (s, 1H, H8). Calculated analysis for C12H11N3O3: C, 58.77; H, 4.48; N, 17.14. Found: C, 58.81; H, 4.65; N, 17.23.
Methyl 2-phenylamide-3-methylquinoxaline-7-carboxylate (DR2)
This compound was obtained in 6.5% yield from methyl 2-phenylamide-3-methylquinoxaline-7-carboxylate 1, 4-di-N-oxide by di-reduced using sodium dithionite. IR (KBr): 3081 (N-H), 2949 (ArC-H), 1722 and 1684 (C=O) cm-1. 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.52 (s, 3H, CH3), 3.99 (s, 3H, CH3OOC), 7.20 (t, J= 7.38 Hz, 1H, H4, NHC6H5), 7.42 (t, J= 7.78 Hz, 2H, H3 and H5, NHC6H5), 7.67 (d, J = 7.92 Hz, H2 and H6, NHC6H5), 8.41 (d, J= 8.84 Hz, H5), 8.62 (d, J= 8.93 Hz, 1H, H6), 9.0 (s, 1H, H8), 11.01 (s, 1H, NH). Calculated analysis for C18H15N3O3: C, 67.28; H, 4.67; N, 13.08. Found: C, 67.15; H, 4.23; N, 12.86.
Ethyl2-(thiophene-2-carbonyl)-3-trifluoromethylquinoxaline-7-carboxylate (DR3)
This compound was obtained in 2.3% yield from ethyl 2-(thiophene-2-carbonyl)-3-trifluoromethylquinoxaline-7-carboxylate 1, 4-di-N-oxide by di-reduced using sodium dithionite. IR (KBr): 2991 (ArC-H), 1722 and 1672 (C=O), 1284 and 1162 (Ar-CF3) cm-1. 1H NMR (400 MHz, DMSO-d6) ppm: 1.41 (t, J= 7.1 Hz, 3H, CH3CH2OOC), 4.47 (q, J1= 7.07 Hz, J2= 7.12 Hz, 2H, CH3CH2OOC), 7.32 (d, J= 4.7 Hz, 1H, H4, C4H3S), 8.24 (d, J= 4.59 Hz, H5, C4H3S), 8.3 (d, J= 4.8 Hz, H3, C4H3S), 8.51 (d, J= 8.95 Hz, 1H, H5), 8.56 (d, J= 8.96 Hz, 1H, H6), 8.96 (s, 1H, H8). Calculated analysis for C17H11F3N2O3S: C, 53.61; H, 2.89; N, 7.35. Found: C, 53.46; H, 2.75; N,
7.23. Compounds derivatives from quinoxaline-7-carboxylate 1ˏ4-di-N-oxide (M1-M3, E1-E8, and P1-P3) and quinoxaline di-reduced derivatives (DR1-DR3) are shown in Table 1.
Biological assays
The National Cancer Institute (NCI) of the United States of America selected the 17 compounds cited above to be evaluated for their in vitro antitumor activity. Initially, all compounds were tested at a single high dose (10-5 M) according to NCI-60 human tumor cell line screen. The human tumor cell lines are grown in RPMI 1640 medium (5% fetal bovine serum and 2 mM L-glutamine). Cells are seeded into 96 well microtiter plates in 100 μL (5,000 to 40,000 cells/well). After, the microtiter plates are incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity for 24 h. Aliquots of 100 μL experimental drugs are added to the appropriate microtiter wells already containing 100 μL of medium, resulting in the required final drug concentration. After, the plates are incubated for an additional 48 h at 37 °C, 5% CO2, 95% air, and 100% relative humidity. For adherent cells, the assay is terminated by the addition of cold TCA. Cells are fixed in situ by the addition of 50 μL of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 minutes at 4 °C. The supernatant is discarded, and the plates are washed five times with water and air dried. Sulforhodamine B (SRB) solution (100 μL) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 minutes at room temperature. After staining, unbound dye is removed by washing five times with 1% acetic acid and the plates are air dried. Bound stain is subsequently solubilized with 10 mM trizma base, and the absorbance is read on an automated plate reader at a wavelength of 515 nm. After, only compounds M3, E5, E6, E7 and P3 were evaluated against the NCI-60 cell panel at five concentrations (0.01, 0.1, 1, 10 and 100 µm) and Growth Inhibition of 50% (GI50) was calculated. Total Growth Inhibition (TGI) and the Lethal Concentration 50 (LC50) were calculated for each cell line according to NCI methodology (15). Data are express in Molar concentration. The GI50 value corresponds to the concentration of the compound causing 50% decrease in net cell growth, the TGI value or cytostatic activity reported is the concentration of the compound resulting in total growth inhibition and the LC50 value corresponds to the cytotoxic activity and it is the concentration of the compound causing 50% loss of initial cells at the end of the incubation period (15).

Results and Discussion

In this study, seventeen derivatives from methyl (M1-M3), ethyl (E1-E8) and n-propyl (P1-P3) quinoxaline-7-caboxylate 1ˏ4-di-N-oxide and three di-reduced quinoxaline (DR1-DR3) derivatives (Table 1) were selected for in-vitro evaluation on 60 human tumor cell lines. Results are reported in Table 2. The number reported is growth relative to the no-drug control cells and it allows detection of both growth inhibition (values between 0-100) and lethality or cytotoxic activity (negative numbers). Compounds which reduce the growth of anyone of the cancer cell lines to 32% or values less are identified as “active” compounds (19).
Table 1Quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives selected by the National Cancer Institute for in-vitro evaluation on 60 human tumor cell lines

Compounds DR1, DR2 and DR3, are di-reduced N-oxide derivatives.

Table 2Cell growth inhibitory activity of ester of quinoxaline 1, 4-di-N-oxide at single dose assay (10-5 M).
Panel/Cell LineM3E5E6E7P3
Leukemia
CCRF-CEM--18.11-44.04--64.45
HL-60(TB)--65.92-69.01--71.61
K-562--76.68-52.64--73.97
MOLT-4--56.44-67.27--63.33
RPMI-8226-48.008.56-45.28-66.78-
SR--59.23-42.78--41.36
Non-Small Cell Lung Cancer
A549/ATCC28.6519.21-94.87-26.42-88.10
EKVX-46.3029.13-76.99-56.85-
HOP-62-9.0825.51-90.62-93.79-96.53
HOP-92-57.01-29.91-83.55--
NCI-H226-17.1441.18-54.87-93.70-
NCI-H23-62.22-16.94-87.04-88.42-75.58
NCI-H322M66.1994.36-87.6467.25-91.67
NCI-H460-88.77-50.66-73.66-100.0-69.92
NCI-H522-80.74-83.76-83.29-80.11-92.62
Colon Cancer
COLO 205-100.0-78.26-84.79-100.0-92.30
HCC-2998-86.89-17.11-88.97-97.59-87.59
HCT-116-97.97-38.94-96.22-100.0-73.00
HCT-15-77.54-35.95-72.03-96.09-65.74
HT29-56.03-0.88-82.43-97.43-92.15
KM12-93.54-85.51-90.43-91.99-81.61
SW-620-18.07-0.80-82.37-89.55-82.53
CNS Cancer
SF-268-24.84-51.82-89.64-88.82-81.45
SF-295-45.7223.01-88.04-84.83-
SF-539-45.8529.71-83.81-100.0-95.02
SNB-19-6.4417.38-77.39-85.51-88.91
SNB-75-20.5325.58-100.0-100.0-98.51
U251-72.256.14-100.0-100.0-
Melanoma
LOX IMVI-95.27-59.67--97.52-74.66
MALME-3M-26.39-39.95--69.07-73.71
M14-25.538.64-96.58-100.0-70.27
MDA-MB-4350.462.85-80.51-78.00-89.53
SK-MEL-2-31.8912.15-87.29-83.53-87.58
SK-MEL-2826.9627.93-93.63-96.34-96.78
SK-MEL-5-100.0-94.33-96.90-100.0-
UACC-257-30.25-37.08-90.39-71.67-94.25
UACC-62-32.682.99-80.42-97.18-92.36
Ovarian cancer
IGROV1-78.34-81.07-60.32-82.94-74.39
OVCAR-3-92.82-84.74-96.63-99.57-95.33
OVCAR-4-41.96-5.96-83.35-65.84-73.09
OVCAR-5-12.93-1.19-79.81-98.53-87.75
OVCAR-89.07-42.56-36.423.25-85.96
NCI/ADR-RES-40.716.85-70.41-86.40-43.06
SK-OV-3-31.4124.84-97.55-100.0-99.91
Renal cancer
786-0-40.5211.40-92.27-100.0-81.24
A4986.7912.45--62.39-90.87
ACHN-99.325.29-86.94-100.0-91.76
CAKI-1-78.4940.03-85.42-93.78-92.47
RXF 393-20.1431.61-92.28-71.20-93.23
SN 12C-33.994.58-47.28-99.16-92.33
TK-1025.9540.92-96.50-89.68-99.13
UO-31-81.9727.45-92.40-96.00-89.00
Prostate cancer
PC-3-58.10-45.68-75.44-99.18-91.49
DU-1451.28-88.45-96.54-100.0-97.17
Breast Cancer
MCF7-50.33-6.41-68.11-93.12-69.69
MDA-MB-231/ATCC-4.6922.16-76.77-99.39-90.36
HS 578T-19.36-23.86-10.78-45.74-52.01
BT-549-19.57-44.86-93.36-48.46-83.94
T-47D-73.64-26.07-70.45-91.10-83.21
MDA-MB-468-83.72-37.04-80.51-92.65-81.36
Mean-41.01-14.73-79.03-82.89-82.75
Delta58.9979.6020.9717.1117.16
Range166.19188.6989.22167.2558.55
Table 3Log10 GI50, Log 10 TGI, and Log 10 LC50 of the in vitro inhibitory activity test for compounds M-3, E-5, E-6, E-7 and P-3 against 60 human tumor cells lines
M-3E-5E-6E-7P-3
Panel/Cell LineLog 10 GI50Log 10 TGILog 10 LC50Log 10 GI50Log 10 TGILog 10 LC50Log 10 GI50Log 10 TGILog 10 LC50Log 10 GI50Log 10 TGILog 10 LC50Log 10 GI50Log 10 TGILog 10 LC50
Leukemia
CCRF-CEM-5.34-4.0> -4.0-5.73-5.27-4.25-6.67-6.32-5.86-6.40-5.64> -4.0-5.73-5.40-5.07
HL-60(TB)-5.71-5.10> -4.0-5.73-5.42-5.11-6.56-6.07-5.25-6.01-5.55-5.09-5.71-5.41-5.11
K-562-5.64-5.11> -4.0-5.97-5.60-5.23-6.72-6.41-6.10-6.51-5.82-5.23-5.68-5.39-5.09
MOLT-4-5.53-4.75> -4.0-5.81-5.23-4.18-6.62-6.28-5.54-5.93-5.48--5.69-5.39-5.09
RPMI-8226-5.65-5.20> -4.0-5.78-5.30-4.17-5.77-5.35-4.26-5.96-5.44> -4.0-5.71-5.39-5.06
SR-5.64-5.10> -4.0----6.68-6.38-6.07-6.48-5.80> -4.0-5.72-5.31-4.0
Non-Small Cell Lung Cancer
A549/ATCC-5.71-5.43-5.15-5.605.24-4.0-6.74-6.44-6.14-5.72-5.44-5.16-5.78-5.48-5.18
EKVX-5.71-5.36-5.01-5.75-5.40-5.05-5.89-5.56-5.22-5.81-5.50-5.20---
HOP-62-5.71-5.43-5.15-5.82-5.48-5.13-6.16-5.70-5.35-5.78-5.51-5.24-5.75-5.47-5.20
HOP-92-5.83-5.50-5.18-5.84-5.55-5.26-6.77-6.05-5.46-5.92-5.60-5.28-5.95-5.62-5.28
NCI-H226-5.71-5.44-5.16-5.74-5.37-4.98-6.16-5.60-5.14-5.76-5.45-5.13-5.69-5.33-4.0
NCI-H23-5.74-5.47-5.20-5.84-5.48-5.11-6.01-5.64-5.28-6.30-5.75-5.37-5.75-5.47-5.19
NCI-H322M-5.37-4.86-4.36-5.62-5.17-4.58-5.80-5.52-5.24-5.79-5.52-5.26-5.74-5.48-5.23
NCI-H460-5.74-5.46-5.18-5.88-5.57-5.27-6.65-6.25-5.64-5.77-5.49-5.22-5.69-5.37-5.05
NCI-H522-5.78-5.48-5.19-5.82-5.44-5.06-6.67-6.23-5.61-6.34-5.73-5.32-5.74-5.46-5.17
Colon Cancer
COLO 205-5.71-5.40-5.10-5.83-5.53-5.23-6.59-6.22-5.67-5.82-5.54-5.26-5.68-5.41-5.15
HCC-2998-5.75-5.50-5.24-5.90-5.57-5.23-6.11-5.68-5.31-5.78-5.52-5.26-5.74-5.48-5.22
HCT-116-5.84-5.56-5.28-5.92-5.56-5.20-6.77-6.50-6.23-6.43-5.84-5.42-5.77-5.47-5.18
HCT-15-5.74-5.45-5.17-5.84-5.44-5.05-6.63-6.20-5.59-5.83-5.48-5.14-5.79-5.48-5.18
HT29-5.76-5.49-5.22-5.79-5.49-5.18-6.77-6.50-6.22-5.97-5.64-5.32-5.68-5.39-5.11
KM12-5.75-5.50-5.24-5.83-5.52-5.21-6.13-5.68-5.31-5.90-5.60-5.30-5.74-5.46-5.18
SW-620-5.71-5.42-5.12-5.80-5.42-5.04-6.78-6.47-6.16-5.82-5.54-5.25-5.73-5.43-5.14
CNS Cancer
SF-268-5.76-5.49-5.22-5.84-5.53-5.21-6.73-6.42-6.10-5.94-5.63-5.31-5.75-5.4-5.17
SF-295-5.87-5.56-5.24-5.87-5.54-5.21-5.90-5.59-5.28-5.75-5.50-5.25-5.77-5.49-5.21
SF-539-5.73-5.47-5.21-5.79-5.51-5.23-5.93-5.62-5.31-5.81-5.54-5.27-5.75-5.49-5.24
SNB-19-5.51-5.04-4.52-5.73-5.39-5.04-5.94-5.61-5.29-5.77-5.51-5.26-5.76-5.49-5.23
SNB-75-5.85-5.57-5.28-5.81-5.52-5.24-5.93-5.62-5.31-5.95-5.63-5.32-5.83-5.52-5.22
U251-5.75-5.49-5.23-5.81-5.51-5.21-6.79-6.53-6.26-5.82-5.55-5.27-5.76-5.49-5.23
Melanoma
LOX IMVI-5.77-5.49-5.22-5.85-5.52-5.20-6.77-6.50-6.24-6.76-6.48-6.21-5.77-5.47-5.18
MALME-3M-5.71-5.42-5.14-5.81-5.52-5.22-6.50-5.84-5.32-5.77-5.46-5.15-5.71-5.44-5.17
M14-5.76-5.49-5.23-5.79-5.44-5.08-6.18-5.70-5.33-5.84-5.56-5.28-5.74-5.47-5.20
MDA-MB-435-5.76-5.44-5.13-5.82-5.52-5.22-6.61-6.24-5.70-5.82-5.53-5.24-5.77-5.49-5.21
SK-MEL-2-5.65-5.32-4.91-5.69-5.29-4.48-5.76-5.48-5.20-5.74-5.47-5.20-5.73-5.45-5.17
SK-MEL-28-5.37-4.88-4.44-5.44-4.89-4.43-5.76-5.51-5.25-5.78-5.52-5.26-5.73-5.45-5.18
SK-MEL-5-5.77-5.51-5.26-5.84-5.56-5.27-5.86-5.57-5.29-5.84-5.56-5.27-5.78-5.51-5.23
UACC-257-5.74-5.48-5.22-5.72-5.42-5.12-6.50-5.90-5.45-5.75-5.49-5.23-5.76-5.49-5.23
UACC-62-5.77-5.50-5.24-5.86-5.54-5.23-5.98-5.64-5.29-5.82-5.53-5.25-5.76-5.49-5.22
Ovarian Cancer
IGROV1-5.76-5.47-5.18-5.80-5.40-5.0-6.72-6.43-6.15-6.44-5.92-5.44-5.74-5.44-5.15
OVCAR-3-5.74-5.49-5.23-5.81-5.51-5.20-6.38-5.84-5.40-6.13-5.69-5.35-5.76-5.50-5.24
OVCAR-4-5.70-5.36--5.75-5.41-5.08-6.66-6.27-5.60-6.58-6.07-5.31-5.76-5.47-5.19
OVCAR-5-5.78-5.51-5.24-5.81-5.49-5.16-5.91-5.60-5.29-5.89-5.59-5.30-5.75-5.48-5.21
OVCAR-8-5.54-5.08-4.34-5.57-4.91-4.0-6.70-6.38-6.05-5.89-5.57-5.24-5.74-5.45-5.16
NCI/ADR-RES-5.61-5.19-4.10-5.72-5.15-4.0-6.54-6.06-5.31-5.79-5.48-5.17-5.72-5.43-5.14
SK-OV-3-5.65-5.35-5.04-5.79-5.49-5.20-5.86-5.58-5.29-5.79-5.52-5.26-5.72-5.48-5.23
Renal Cancer
786-0-5.72-5.47-5.23-5.80-5.52-5.23-6.27-5.73-5.32-5.79-5.52-5.26-5.74-5.48-5.22
A498-5.76-5.48-5.20-5.87-5.43-4.96-5.79-5.51-5.22-5.78-5.51-5.24-5.89-5.55-5.21
ACHN-5.75-5.49-5.23-5.80-5.52-5.23-6.77-6.51-6.26-5.83-5.53-5.23-5.75-5.49-5.22
CAKI-1-5.71-5.29-4.54-5.84-5.51-5.18-6.67-6.24-5.62-5.85-5.54-5.24-5.75-5.47-5.19
RXF 393-5.69-5.41-5.14-5.59-5.06-4.19-6.02-5.66-5.32-5.76-5.49-5.21-5.77-5.49-5.21
SN 12C-5.62-5.31--5.73-5.42-5.10-6.34-5.72-5.21-5.79-5.45-5.10-5.75-5.47-5.20
TK-10-5.56-5.22-4.71-5.78-5.41-5.03-6.75-6.47-6.19-5.72-5.48-5.24-5.80-5.52-5.25
UO-31-5.77-5.50-5.24-5.83-5.50-5.18-6.82-6.54-6.25-5.89-5.59-5.30-5.78-5.51-5.25
Prostate Cancer
PC-3-5.78-5.44-5.10-5.93-5.57-5.22-6.44-5.82-5.30-6.14-5.70-5.34-5.81-5.53-5.25
DU-145-5.74-5.49-5.24-5.81-5.52-5.24-6.06-5.68-5.34-5.75-5.50-5.25-5.73-5.48-5.23
Breast Cancer
MCF7-5.76-5.47-5.19-5.93-5.60-5.26-6.44-5.885.32-6.05-5.62-5.22-5.79-5.48-5.17
MDA-MB-231/ATCC-5.70-5.41-5.12-5.76-5.45-5.13-6.40-5.81-5.37-5.80-5.50-5.20-5.72-5.46-5.20
HS 578T-5.63-5.23-4.0-5.84-5.35-4.20-5.67-5.20-4.0-5.80-5.44-5.08-5.70-5.34-4.00
BT-549-5.68-5.355.01-5.84-5.53-5.22-6.31-5.75-5.36-5.81-5.48-5.15-5.75-5.49-5.22
T-47D-5.69-5.38-5.07-5.85-5.48-5.11-6.31-5.73-5.28-6.07-5.64-5.25-5.74-5.43-5.12
MDA-MB-468-5.81-5.52-5.23-5.80-5.48-5.17-6.51-5.78-5.29-6.43-5.82-5.39-5.77-5.45-5.14
In the development of new anticancer drugs, tirapazamine, a quinoxaline 1,4-di-N-oxide derivative, is a potent antitumor agent, with a simple structure (small molecule) which induce a strong toxicity against a variety of tumor human cell (20). Therefore, our research group design and obtained new ester of quinoxaline 1, 4-di-N-oxide as potential antitumor agent. As shown in table 1, when analysing the compounds at single dose assay, compounds M3, E5, E6, E7 and P3 showed the highest global activity against the 60 human tumor cell lines tested. In all cases these compounds showed a negative final mean indicating cytotoxicity activity at 10-5 M (-41.01, -14.73, -79.03, -82.89 and -82.75 respectively). In contrast to the other active compounds mentioned above, E5 do not show lethality against any of the renal cancer cells (values ranging 4.58 to 40.92). All other compounds showed little or no activity. None active compound showed selectivity to certain tumor cell type. As M3, E5, E6, E7 and P3 showed the highest anticancer activity, they were selected and assayed at five dose level against the same 60 human tumor cell lines panel. Results (Table 3) showed that compounds tested showed an excellent antitumor activity. E6 a quinoxaline 1ˏ4-di-N-oxide with ethyl ester at 7-position, was the most active with the lowest GI50, TGI and LC50 values against all the cell lines tested regardless of the tumour cell type, showing no selectivity. E7 showed its higher activity against leukemia and ovarian panel, while M3 showed good activity against the different tumour cell types except for leukemia with Log10 LC50 values >-4.0 M.Structure-activity relationship (SAR) analysis of methyl quinoxaline-7-carboxylate 1ˏ4-di-N-oxide (M1-M3) series shows that substitution at 3-position with electronegative group (CF3) play a very important role in the cytotoxicity activity, enhancing drastically biological effect. The same biological behaviour can be detected in ethyl (E1-E7) and n-propyl (P1-P3) quinoxaline-7-carboxylate 1ˏ4-di-N-oxide series, because only compounds substituted at 3-position with CF3 group showed inhibitory effect. Furthermore, the importance in the cytotoxic activity of CF3 group at 3-position on quinoxaline ring has been showed in the design and obtention of potent antitumor agents by Zarranz and cols (6). Substitutions at 2-position on quinoxaline 1,4-di-N-oxide ring increase the activity in the following order: naphthyl > thiophenyl > methyl. These results showed that aromatic and coplanar groups at 2-position are very important to enhance biological activity. This same key biological behaviour has been reported by other authors (6, 10). Finally, analysing compounds M3 and E5 shows that substitutions at 7-position with esters group not necessarily affect the cytotoxic activity, but the nature of this esters group could exert a strong influence on the selectivity. However, Ismail and cols mentioned that incorporation of halogen atom at 6 or 7-position could enhance activity, therefore, this is a point to consider in the near future to development new antitumor agents (12). Additionally results of compounds DR1-DR3 showed a great role of N-oxide group in the cytotoxic effects as previously has been reported (10, 12).

Conclusion

In the light of these results and in order to further explore for this class of compounds, in the present study we reported the cytotoxic activities of ester of quinoxaline 1ˏ4-di-N-oxide derivatives selected by the NCI. The antitumor activity of all these compounds was evaluated against the NCI-60 cell line panel at a single dose assay (10-5 M) according to their own protocols. Five of the tested compounds were active ranging their activity from cytostatic to cytotoxic agents depending of the cell line used. Among the examined series, we found that compounds E7, P3 and E6 were the most active against all 60 human cell lines with global mean values of -82.89, -82.75 and -79.03 respectively. None compound showed selectivity to certain cancer cell type or to a particular cell line except E5, that was also considered active (-14.73) but do not show lethality against any of the renal cancer cells. The results of this investigation prompt us to continue the development and testing of novel quinoxaline 1ˏ4-di-N-oxide derivatives and importantly to carry out further studies to investigate their potential mechanisms of action.

Acknowledgments

References

  • 2.
    Jaso A, Zarranz B, Aldana I, Monge A. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1, 4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur. J. Med. Chem. 2003;38:791-800. [PubMed ID: 14561478].
  • 3.
    El-Sabbagh OI, El-Sadek ME, Lashine SM, Yassin SH, El-Nabtity SM. Synthesis of new 2 (1H)-quinoxalinone derivatives for antimicrobial and antiinflammatory evaluation. Med. Chem. Research. 2009;18:782-97.
  • 4.
    Shibinskaya MO, Karpenko AS, Lyakhov SA, Andronati SA, Zholobak NM, Spivak NY, Samochina NA, Shafran LM, Zubritsky MJ, Galat VF. Synthesis and biological activity of 7H-benzo(4,5)indolo(2,3-b)-quinoxaline derivatives. Eur. J. Med. Chem. 2011;46:794-8. [PubMed ID: 21172726].
  • 5.
    Barea C, Pabón A, Castillo D, Zimic M, Quiliano M, Galiano S, Pérez-Silanes S, Monge A, Deharo E, Aldana I. New salicylamide and sulfonamide derivatives of quinoxaline 1, 4-di-N-oxide with antileishmanial and antimalarial activities. Bioorg. Med. Chem. Lett. 2011;21:4498-502. [PubMed ID: 21724395].
  • 6.
    Zarranz B, Jaso A, Aldana I, Monge A. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1, 4-di-N-oxide derivatives. Bioorg. Med. Chem. 2004;12:3711-21. [PubMed ID: 15186857].
  • 7.
    Corona P, Carta A, Loriga M, Vitale G, Paglietti G. Synthesis and in-vitro antitumor activity of new quinoxaline derivatives. Eur. J. Med. Chem. 2009;44:1579-91. [PubMed ID: 18774202].
  • 8.
    Noolvi MN, Patel HM, Bhardwaj V, Chauhan A. Synthesis and in-vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent. Eur. J. Med. Chem. 2011;46:2327-46. [PubMed ID: 21458891].
  • 9.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M, Hamilton E, Barker AJ, Clarke ED, Greenhow DT. Hypoxia-selective agents derived from quinoxaline 1, 4-di-N-oxides. J. Med. Chem. 1995;38:1786-92. [PubMed ID: 7752202].
  • 10.
    Ortega MA, Morancho MJ, Martínez-Crespo FJ, Sainz Y, Montoya ME, López de Ceráin A, Monge A. New quinoxalinecarbonitrile 1ˏ4-di-N-oxide derivatives as hypoxic-cytotoxic agents. Eur. J. Med. Chem. 2000;35:21-30. [PubMed ID: 10733600].
  • 11.
    Amin KM, Ismail MM, Noaman E, Soliman DH, Ammar YA. New quinoxaline 1ˏ4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1ˏ4-di-N-oxides. Bioorg. Med. Chem. 2006;14:6917-23. [PubMed ID: 16843668].
  • 12.
    Ismail MM, Amin KM, Noaman E, Soliman DH, Ammar YA. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents. Eur. J. Med. Chem. 2010;45:2733-38. [PubMed ID: 20236735].
  • 13.
    Burguete A. Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1, 4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4, 5-dihydro-(1H)-pyrazole analogues. Bioorg. Med. Chem. Lett. 2007;17:6439-43. [PubMed ID: 17942306].
  • 14.
    Solano B, Junnotula V, Marín A, Villar R, Burguete A, Vicente E, Pérez-Silanes S, Aldana I, Monge A, Dutta S. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1, 4-di-N-oxide derivatives and their reduced analogues. J. Med. Chem. 2007;50:5485-54. [PubMed ID: 17910426].
  • 15.
    Shoemaker RH. The NC160 Human Tumour Cell line Anticancer Drug Screen. Nat. Rev. Cancer. 2006;6:813-23. [PubMed ID: 16990858].
  • 16.
    Gomez-Caro L, Sanchez-Sanchez M, Bocanegra-Garcia M, Rivera G, Monge A. Florisil and montmorillonite KSF and K10 catalyzed synthesis of quinoxaline 1ˏ4-di-N-oxide derivatives by free-solvent and microwave-assisted procedure. Quimica Nova. 2011;34:1147-51.
  • 17.
    Duque-Montaño BE, Gómez-Caro LC, Sanchez-Sanchez M, Monge A, Hernández-Baltazar E, Rivera G, Torres-Angeles O. Synthesis and in-vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1ˏ4-di-N-oxide against Entamoeba histolytica. Bioorg. Med. Chem. 2013;21:4550-8. [PubMed ID: 23787289].
  • 18.
    Montoya ME, Sainz Y, Ortega MA, De Cerain AL, Monge A. Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. II Farmaco. 1998;53:570-73.
  • 19.
    Corona P, Carta A, Loriga M, Vitale G, Paglietti G. Synthesis and in-vitro antitumor activity of new quinoxaline derivatives. Eur. J. Med. Chem. 2009;44:1579-91. [PubMed ID: 18774202].
  • 20.
    Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin. Investig. Drugs. 2009;18:77-87.

Similar Articles

31
Jan
2016

Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents

Walaa S. El-serwy,
Neama A. Mohamed,
Emad M. M. Kassem,
Khaled Mahmoud,
M. M Mounier

El-serwy WS, A. Mohamed N, M. M. Kassem E, Mahmoud K, Mounier MM. Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents. Iran J Pharm Res. 2016;15(1):e125119. doi: https://doi.org/10.22037/ijpr.2016.1799

20
Nov
2017
Can Functionalization of Quinoline Derivatives Be Exploited to Control Quinolines Cytotoxic Effects?

Can Functionalization of Quinoline Derivatives Be Exploited to Control Quinolines Cytotoxic Effects?

Zahra Hami,
Ramin Zibaseresht

Hami Z, Zibaseresht R. Can Functionalization of Quinoline Derivatives Be Exploited to Control Quinolines Cytotoxic Effects?. J Arch Mil Med. 2017;5(4):e58194. doi: https://doi.org/10.5812/jamm.58194

30
Apr
2017

Synthesis, In-Vitro Activity and Metabolic Properties of Quinocetone and Structurally Similar Compounds

Keyu Zhang,
Chunmei Wang,
Xiaoyang Wang,
Haihong Zheng,
Juan Zhao,
Mi Wang
,et al.

Zhang K, Wang C, Wang X, Zheng H, Zhao J, et al. Synthesis, In-Vitro Activity and Metabolic Properties of Quinocetone and Structurally Similar Compounds. Iran J Pharm Res. 2017;16(2):e125004. doi: https://doi.org/10.22037/ijpr.2017.2039

31
Jul
2012

Synthesis of Some New Quinazolinone Derivatives and Evaluation of Their Antimicrobial Activities

Ghadamali Khodarahmi,
Elham Jafari,
Gholamhossein Hakimelahi,
Daryoush Abedi,
Marzieh Rahmani Khajouei,
Farshid Hassanzadeh

Khodarahmi G, Jafari E, Hakimelahi G, Abedi D, Rahmani Khajouei M, et al. Synthesis of Some New Quinazolinone Derivatives and Evaluation of Their Antimicrobial Activities. Iran J Pharm Res. 2012;11(3):e125820. doi: https://doi.org/10.22037/ijpr.2012.1123

31
Oct
2015

Novel N-2-(Furyl)-2-(chlorobenzyloxyimino) Ethyl Piperazinyl Quinolones: Synthesis, Cytotoxic Evaluation and Structure-Activity Relationship

Negar Mohammadhosseini,
Mahboobeh Pordeli,
Maliheh Safavi,
Loghman Firoozpour,
Fatame Amin,
Sussan Kabudanian Ardestani
,et al.

Mohammadhosseini N, Pordeli M, Safavi M, Firoozpour L, Amin F, et al. Novel N-2-(Furyl)-2-(chlorobenzyloxyimino) Ethyl Piperazinyl Quinolones: Synthesis, Cytotoxic Evaluation and Structure-Activity Relationship. Iran J Pharm Res. 2015;14(4):e125399. doi: https://doi.org/10.22037/ijpr.2015.1733

Import into EndNoteImport into BibTex
Crossmark
Crossmark
Checking
Share on
Comments
Number of Comments:0
Cited by
Metrics
Licensing and reuse information

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles

Related Article in PubMed

Related Article in Google Scholar

Create Citation Alert via Google Reader